Covid-19 Vaccine Response in Immunocompromised Haematology Patients [COVID-19]
Research type
Research Study
Full title
A single-centre, observational study to evaluate immune response to Covid-19 vaccines in immunocompromised patients with haematological disorders
IRAS ID
294869
Contact name
Deepak Chandra
Contact email
Sponsor organisation
University Hospitals of North Midlands NHS Trust
Duration of Study in the UK
0 years, 11 months, 28 days
Research summary
Coronavirus (Covid-19) has affected millions of people worldwide. Vaccines to prevent Covid-19 infection are being offered to reduce the risk of infection. While these vaccines are being offered to people with suppressed immunity they have not been tested in these individuals. It is uncertain whether people with suppressed immunity (like patients with certain blood disorders or those who have received certain immunosuppressive treatment) will develop protective antibodies after a Covid-19 vaccination. It is also uncertain how long these antibodies will last in these individuals.
We are planning to study the immune response to the first dose of Covid-19 vaccine in people with suppressed immunity due to certain blood disorders and treatments (study group) and compare this to people with normal immunity (control group).
REC name
London - London Bridge Research Ethics Committee
REC reference
21/HRA/0304
Date of REC Opinion
2 Mar 2021
REC opinion
Favourable Opinion